Anthocyanins and cardiovascular diseases


It has been scientifically proven that anthocyanins reduce the risk of cardiovascular diseases and cancer and also 
have antimicrobial and anti-inflammatory effects. Multiple risk markers for atherosclerosis and cardiovascular 
disease act in a synergistic way through inflammatory pathways. The influence of chronic inflammation in endothelial 
cells, smooth muscle cells, and immune cells play a crucial role in cardiovascular pathology.

Biolink Group has together with university hospitals performed different clinic studies to document the effects of 
the most biologic active anthocyanins in the cardiovascular system.
 
A large, double blind, randomized placebo controlled human study at the University Hospital of Ullevål, Oslo, 
found anthocyanins(Medox®) significant to lower sedimentation rate and resting pulse.
 
These findings led to 3 new pilot mice studies at the University Hospital of Ullevål, Oslo, investigating the two 
anthocyanins, Cyanidin and Delphinidin`s influense on the resting pulse and hypertension. Results on all pilot 
studies has been promising enough to result in new, larger clinical studies.

A new clinic placebo controlled mice study is being performed at The University Hospital of Ullevål  evaluating 
the effects of the synthetic anthocyanins (BSCyanidin 3G and BSDelphinidin 3G) on resting pulse and on hypertension